Zevra Therapeutics reports developments as a commercial-stage biopharmaceutical company focused on therapies for rare diseases. Recurring updates center on MIPLYFFA (arimoclomol), its U.S.-approved treatment for Niemann-Pick disease type C, including commercialization, patient access, regulatory activity and diagnostic-support initiatives tied to NPC.
Zevra news also covers financial results, pipeline programs in rare diseases such as vascular Ehlers-Danlos syndrome, and corporate actions that shape its portfolio. Recent company updates include the completed sale of the serdexmethylphenidate, or SDX, portfolio, including AZSTARYS and KP1077, as well as governance and executive-compensation announcements under Nasdaq rules.
Zevra Therapeutics (Nasdaq: ZVRA) will report fourth quarter and full year 2025 corporate and financial results on Monday, March 9, 2026 after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. The live webcast link and replay will be available on the company’s Investor Relations Events & Presentations page.
Telephone dial-ins include a U.S. number and an international number; a replay will be available for 90 days beginning about 5:30 p.m. ET.
Zevra Therapeutics (Nasdaq: ZVRA) announced that its executive leadership will present at the Citizens Life Sciences Conference in Miami Beach on March 11, 2026 at 9:00 a.m. ET.
Management will hold one-on-one meetings with registered attendees and a live webcast will be available via the Events & Presentations page on Zevra's investor website.
Zevra Therapeutics (NasdaqGS: ZVRA) presented four posters at the 22nd Annual WORLDSymposium on MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C (NPC).
Key highlights: four-year U.S. Early Access Program (EAP) data showing tolerability and disease stabilization across pediatric and adult patients, a post hoc NPC002 analysis showing statistically significant slowing versus placebo from month 3 through 12, and the first multi-year adult NPC dataset.
Zevra Therapeutics (Nasdaq: ZVRA) will ring the Nasdaq opening bell on Monday, February 9, 2026. CEO Neil F. McFarlane will deliver opening remarks at 9:24 a.m. ET followed by the bell at 9:30 a.m. ET. The ceremony is viewable via Nasdaq's live stream and on the Nasdaq MarketSite Tower in New York.
Zevra Therapeutics (Nasdaq: ZVRA) will present four abstracts on MIPLYFFA® (arimoclomol) at the 22nd Annual WORLDSymposium™ in San Diego, Feb 2-6, 2026. Four-year real-world safety and effectiveness data in Niemann-Pick disease type C (NPC) will be presented orally by Caroline Hastings, MD on Thursday, Feb 5, 2026 at 2:30 p.m. PT.
Three poster presentations on Feb 5 at 3:30 p.m. PT cover the U.S. Early Access Program (EAP), multi-year subgroup analyses, and efficacy from a randomized, placebo-controlled trial including arimoclomol plus miglustat. Zevra will host a non-CE satellite symposium on NPC diagnostics and therapeutics on Feb 5 at 12:15 p.m. PT. E-posters available via the WORLDSymposium app beginning Feb 3, 2026 at 5:00 p.m. PT, with on-demand access Feb 11–Mar 13, 2026. Zevra staff will be at booths #213 and #507 during the meeting.
Zevra Therapeutics (NASDAQ: ZVRA) said its executive leadership will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 15, 2026 at 9:45 a.m. PT. Management will also hold one-on-one meetings with registered attendees. A live webcast will be available via the company’s Investor Relations "Events & Presentations" page at investors.zevra.com.
Zevra Therapeutics (Nasdaq: ZVRA) executed an exclusive expanded access distribution agreement with Uniphar to broaden patient access to MIPLYFFA (arimoclomol) for reimbursed named-patient supply in select territories outside Europe. MIPLYFFA is FDA-approved and commercially available in the U.S.; a Marketing Authorisation Application for NPC has been validated and is under review by the European Medicines Agency. Zevra said the deal leverages Uniphar’s global distribution capabilities while the company continues U.S. commercialization and prepares for potential EU approval.
Zevra Therapeutics (Nasdaq: ZVRA) announced on Dec 12, 2025 that it granted options to purchase an aggregate of 53,000 shares of common stock as inducement awards to three new employees under its 2023 Employment Inducement Award Plan. Each award vests over four years with 25% vesting on the first anniversary of employment and the remainder in three equal annual installments, subject to continued employment.
Each award was granted as an inducement material to the individual entering employment in accordance with Nasdaq Rule 5635(c)(4). The Inducement Award Plan is reserved for individuals not previously employed or returning after a bona fide non-employment period.
Zevra Therapeutics (NasdaqGS: ZVRA) announced on December 2, 2025 the appointment of Alicia Secor to its Board of Directors and the retirement of director Wendy Dixon, PhD, effective the same date. The company said Secor brings more than 30 years of life sciences experience, including recent roles as President and CEO of Atalanta Therapeutics and prior CEO of Juniper Pharmaceuticals (acquired by Catalent in 2018), plus senior leadership at Genzyme and board roles at multiple biotech firms. Zevra’s chair and CEO each commented that Secor’s rare‑disease expertise will support strategy execution and thanked Dixon for her service.
Zevra Therapeutics (NasdaqGS: ZVRA) announced that Chief Financial Officer and Treasurer R. LaDuane Clifton will step down effective December 31, 2025 to pursue other professional opportunities. Clifton has served since 2015, and company leadership said he helped guide Zevra from development stage to a commercial-stage rare disease company and left a strong financial foundation.
The company has initiated a search for a new chief financial officer. No replacement has been named and no financial metrics or guidance changes were disclosed.